Gyros Protein Technologies AB, a provider of automated nanoliter-scale immunoassays and peptide synthesizers and reagents, said Oxford BioMedica, a gene and cell therapy group, has invested in two Gyrolab xPlore systems. This is the first time the Gyrolab technology has been applied within the gene and cell therapy area. Gene and cell therapy has the potential to transform medicine, providing long-term, and potentially curative, treatment options for a wide range of diseases. Several highly p...